Trek Financial LLC Buys 3,927 Shares of Eli Lilly and Company $LLY

Trek Financial LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 181.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 6,096 shares of the company’s stock after buying an additional 3,927 shares during the period. Trek Financial LLC’s holdings in Eli Lilly and Company were worth $6,551,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the last quarter. Miller Global Investments LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $33,000. Finally, Hopwood Financial Services Inc. boosted its stake in Eli Lilly and Company by 113.6% in the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after purchasing an additional 25 shares during the period. 82.53% of the stock is owned by institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Barclays raised its price target on Eli Lilly to $1,400 from $1,350 and kept an Overweight rating, reinforcing the market’s long-term growth case for LLY. Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
• Positive Sentiment: New four-year data for Omvoh (mirikizumab) showed durable disease clearance in ulcerative colitis, strengthening Lilly’s immunology franchise and adding to the company’s growth narrative. Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
• Positive Sentiment: Coverage highlighting Lilly as a top momentum stock and a key name in growth portfolios may keep investor sentiment constructive around the shares. Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: Lilly halted its obesity awareness campaign in India after regulatory scrutiny, suggesting possible compliance friction in an important growth market, though the company is seeking clearer rules. Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity
• Neutral Sentiment: News that Centessa’s sale to Lilly is being examined by a law firm is more of a transaction-process update than a clear driver of Lilly’s operating outlook. Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc – CNTA
• Negative Sentiment: Rival Novo Nordisk’s strength and broader comparisons in GLP-1 and obesity drugs highlight ongoing competitive pressure on Lilly’s key franchise. NVO Rallies 21% in a Month: How Should Investors Play the Stock?

Analyst Upgrades and Downgrades

A number of research analysts have commented on LLY shares. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. TD Cowen boosted their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Finally, Argus lifted their price objective on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.33.

Eli Lilly and Company Trading Up 1.8%

Shares of LLY stock opened at $965.85 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock’s fifty day moving average price is $941.13 and its two-hundred day moving average price is $993.05. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market cap of $909.58 billion, a PE ratio of 34.31, a P/E/G ratio of 1.03 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.